TWA
KRYS icon

TCI Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

TCI Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-84
Closed -$6.73K – 1277
2023
Q1 		$6.73K Sell
84
-1
-1% -$79 ﹤0.01% 1326
2022
Q4 		$6.73K Buy
85
+1
+1% +$74 ﹤0.01% 1341
2022
Q3 		$6K Hold
84
– – ﹤0.01% 1350
2022
Q2 		$6K Hold
84
– – ﹤0.01% 1366
2022
Q1 		$6K Sell
84
-7
-8% -$437 ﹤0.01% 1432
2021
Q4 		$6K Buy
+91
New +$5.3K ﹤0.01% 1543
2021
Q3 		– Sell
-38
Closed -$3K – 2481
2021
Q2 		$3K Buy
38
+14
+58% +$977 ﹤0.01% 1782
2021
Q1 		$2K Buy
+24
New +$1.75K ﹤0.01% 1789

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCI Wealth Advisors's KRYS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 84 shares — an estimated $6.73K sold.

TCI Wealth Advisors first reported a position in KRYS in Q1 2021 and held it in 8 quarters. The position peaked at $6.73K in Q4 2022. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 84 Krystal Biotech shares in Q2 2023, an estimated $6.73K.
  • TCI Wealth Advisors first reported a position in Krystal Biotech in Q1 2021 and held it in 8 quarters.
  • TCI Wealth Advisors's Krystal Biotech position peaked at $6.73K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.